ArticleDiscover oncology2025
A pan-cancer analysis of the oncogenic role of KIF13A in human tumors.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Despite the increasing evidence supporting the association between KIF13A and cancer, pan-cancer analysis is currently limited. Therefore, we aimed to investigate the potential for KIF13A to contribute to oncogenesis in thirty-three different tumors using publicly accessible databases. Our research findings indicate that KIF13A has lower RNA tissue specificity and exhibits lower levels of expression compared to healthy tissue in most of tumor. However, we discovered distinct associations between KIF13A expression and the outcome of diverse tumor types. Genetic variation analysis revealed that cases of UCEC with genetic alterations in KIF13A exhibited a better prognosis compared to cases without genetic alterations in KIF13A. Analysis of differentially methylated genes (DMGs) in pan-cancer studies revealed that the promoter region of KIF13A exhibited significantly different methylation levels between tumor tissues and adjacent normal tissues across various cancer types. Furthermore, we observed differences in KIF13A (NP_017396.4) phosphorylation levels between normal tissues and primary tumor tissues at different phosphorylation sites across various tumor cases. Specifically, we noted an increased phosphorylation level of KIF13A at the S1698 site in HNSC and HCC, correlating with the early differentiation of human embryonic stem cells. Analysis of immune infiltration revealed a bidirectional regulatory pattern, suggesting that KIF13A may differentially shape the tumor microenvironment across cancer types, potentially influencing immunotherapy responses and stromal interactions. Gene enrichment analysis related to KIF13A indicates that it is involved pathways related to vesicle transport, pigment synthesis, and ubiquitination modification. The synergistic effects of these pathways may collectively contribute to the role of KIF13A in tumor pathogenesis. In conclusion, this pioneering pan-cancer study offers thorough comprehension of the role of KIF13A in various cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.